CELZ— CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

MaterialsBiotechnology$5M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$6K-45.5%	$11K+22.2%	$9K-89.8%	$89K
Cost of revenues	$2K-50.1%	$4K+22.2%	$4K-87.4%	$28K
Gross profit	$4K-42.3%	$7K+22.2%	$5K-91.0%	$60K
Research and development	$2.3M-5.9%	$2.4M+21.8%	$2.0M-68.6%	$6.3M
Selling, general and administrative	$3.8M+16.2%	$3.2M-9.0%	$3.6M-9.7%	$3.9M
Amortization of patent costs	$123K+11.7%	$110K+16.8%	$95K+2.7%	$92K
TOTAL EXPENSES	$6.1M+6.9%	$5.8M+2.2%	$5.6M-45.4%	$10.3M
Operating loss	-$6.1M-6.9%	-$5.7M-2.2%	-$5.6M+45.1%	-$10.2M
Interest income	$148K-41.0%	$250K-24.9%	$334K+232.5%	$100K
Total other income (expense)	$148K-41.0%	$250K-24.9%	$334K+232.5%	$100K
LOSS BEFORE PROVISION FOR INCOME TAXES	-$6.0M-9.1%	-$5.5M-3.9%	-$5.3M+47.9%	-$10.1M
Provision for income taxes	$0	$0	$0	$0
NET LOSS	-$6.0M-9.1%	-$5.5M-3.9%	-$5.3M+47.9%	-$10.1M
Net income attributable to non-controlling interest	$0	$0	—	—
NET LOSS ATTRIBUTABLE TO CMTH	-$6.0M-9.1%	-$5.5M-3.9%	-$5.3M+47.9%	-$10.1M
NET LOSS PER SHARE - BASIC AND DILUTED	-$2.52+32.1%	-$3.71+1.3%	-$3.76+59.5%	-$9.28
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	2.4M+61.0%	1.5M+5.2%	1.4M+28.8%	1.1M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.